Atara Biotherapeutics (ATRA) Total Liabilities (2013 - 2026)

Atara Biotherapeutics' Total Liabilities history runs 14 years deep, the most recent figure standing at $57.3 million for Q1 2026.

• Quarterly Total Liabilities fell 51.06% year-over-year to $57.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.3 million (down 51.06% YoY) and the FY2025 annual result came in at $58.7 million, down 71.54% from the prior year.
• Total Liabilities was $57.3 million for Q1 2026 at Atara Biotherapeutics, down from $58.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $264.7 million in Q4 2023 and bottomed at $57.3 million in Q1 2026.
• A 5-year average of $180.4 million and a median of $206.4 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 42.62% — and 2025, when it slumped 71.54%.
• Atara Biotherapeutics' Total Liabilities stood at $249.8 million in 2022, then grew by 5.99% to $264.7 million in 2023, then decreased by 22.04% to $206.4 million in 2024, then slumped by 71.54% to $58.7 million in 2025, then retreated by 2.43% to $57.3 million in 2026.
• Business Quant data shows ATRA's Total Liabilities at $57.3 million in Q1 2026, $58.7 million in Q4 2025, and $66.8 million in Q3 2025.